Skip to main content

Advertisement

Table 2 Baseline characteristics of the study population, overall, and stratified by APOE ε4 genotype

From: CSF level of β-amyloid peptide predicts mortality in Alzheimer’s disease

Characteristics   APOE genotype
AD patients 0 ε4 1 ε4 2 ε4  
(N = 321) (N = 125) (N = 141) (N = 55) P value
Age, year, mean (SD) 71.0 (8.5) 71.4 (9.9) 71.4 (7.6) 69.0 (6.9) 0.07
Women, n (%) 200 (62.3) 76 (60.8) 87 (61.7) 37 (67.3) 0.70
MMSE, mean (SD) 20.3 (5.8) 20.4 (5.6) 19.8 (5.9) 21.4 (5.8) 0.16
Level of education, n (%)
 Low 106 (35.7) 48 (40.3) 44 (33.9) 14 (29.2)  
 Intermediate 110 (37.0) 38 (31.9) 50 (38.5) 22 (45.8)  
 High 81 (27.3) 33 (27.7) 36 (27.7) 12 (25) 0.49
APOE ε4 carriers, n (%) 196 (61.1)
Years of follow-up, mean (SD) 3.9 (2.4) 3.8 (2.5) 3.8 (2.4) 4.1 (2.6) 0.74
Death, n (%) 57 (17.8) 25 (20.0) 24 (17.0) 8 (14.6) 0.65
Institution, n (%) 71 (22.1) 26 (20.8) 35 (24.8) 10 (18.2) 0.54
CSF biomarkers, pg/mL, mean (SD)
 Aβ42 483.8 (134.8) 481.9 (136.1) 512.1 (126.1) 415.9 (130.8) < 0.001
 Aβ40b 13,298 (5454) 12,820 (5648) 13,843 (5498) 12,928 (4897) 0.19
 Ratio Aβ42/40b 0.047 (0.022) 0.049 (0.022) 0.047 (0.024) 0.040 (0.014) 0.08
 Tau 684.9 (276.9) 677.4 (271.4) 705.2 (291.9) 649.5 (248.1) 0.61
 p-Tau 181 102.6 (39.0) 103.6 (46.4) 103.8 (35.0) 97.4 (29.6) 0.60
  1. aLow: primary school or less, intermediate: secondary to high school, high: baccalaureate or university degree
  2. bCSF Aβ40 was available for 214 patients